September 2024 - Portal Instruments welcomes Matt Regan to its Board of Directors. Regan has held extensive leadership roles for prominent pharmaceutical companies such as Abbvie, Novo Nordisk and Micreos.
Matt Regan, a seasoned leader in the healthcare and life sciences industry, has recently joined the Board of Directors at Portal Instruments. This strategic move brings valuable expertise to Portal, a company focused on revolutionizing drug delivery through its innovative needle-free injection technology.
Regan's addition to the board underscores Portal Instruments' commitment to innovation and growth. His pharmaceutical insights and leadership will play a crucial role in shaping the company's future as it continues to advance its technology.
May 9, 2022 - Gerresheimer AG, a leading provider of drug delivery systems, is expanding its portfolio of highly innovative platform technologies for drug delivery, today announcing an investment into US-based Portal Instruments.
July 2020 - Portal Instruments has been selected as a finalist for the 2020 New England Innovation Awards. The Massachusetts Innovation Network is pleased to announce the 25 finalists of the Annual New England Innovation Awards, the oldest and longest-running innovation program in New England.
June 30, 2021 - The National Transgender Discrimination Survey Report on Health and Health Care recorded at least 80% of transgender people have either taken gender-affirming hormone therapy (GAHT) or want to take GAHT at some point.¹
Please fill out the details below and we will get back to you shortly.